Modified International Prognostic Scoring System (IPSS) of Germing et al That Includes the Serum LDH in a Patient with a Myelodysplastic Syndrome (MDS)

Description

Germing et al supplemented the International Prognostic Scoring System (IPSS) by the addition of the patient's serum LDH. This can improve the accuracy of prognostic predictions. The authors are from multiple university hospitals in Germany and Austria.

Patient selection: primary myelodysplastic syndrome (MDS)

Parameters:

(1) IPSS risk group

(2) serum LDH (designated A if normal, B if elevated)

IPSS Risk Group	Serum LDH	Designation	Median Survival in months
low	normal	low A	107
low	elevated	low B	63
intermediate-I	normal	intermediate IA	66
intermediate-I	elevated	intermediate IB	36
intermediate-II	normal	intermediate IIA	26
intermediate-II	elevated	intermediate IIB	16
high	normal	high A	16
high	elevated	high B	11

where:

• Patients with low B and intermediate IA have a similar survival.

• Patients with intermediate IIB and high A have a similar survival.

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10